Key figures
409
m
Revenues in CHF
(2016: 373m)4
| 2017 | 2016 | +/− in % | |
in TCHF | ||||
Order intake2 | 449 736 | 370 246 | 21.5 | |
Gross profit | 256 476 | 247 943 | 3.4 | |
in % of revenues | 62.8 | 63.3 | ||
Investments in non-current assets | 22 201 | 22 827 | –2.7 | |
Free cash flow | –7 582 | 441 | –1 819.3 | |
Net working capital3 | 168 361 | 136 540 | 23.3 | |
in % of revenues | 37.3 | 33.8 | ||
Total assets | 414 458 | 357 060 | 16.1 | |
Net debt (–) / net cash (+) | –10 544 | 17 008 | –162.0 |
23.8%
RONCE
(2016: 26.6%)1
1841
Headcount as at 31.12.2017
(31.12.2016: 633 employees)
2.0%
Dividend yield as at 31.12.2017
(31.12.2016: 2.6%)
59.2%
Payout ratio
(2016: 63.4%)1
1Since the start of 2017, the consolidated financial statements have been drawn up in accordance with Swiss GAAP FER. The prior-year figures have been revised accordingly. The years 2013–2015 are reported according to IFRS.
2Order intake of the Medtech business unit, which was sold in April 2016, is not included.
3Net working capital: receivables + inventories ./. current liabilities.
4Revenues of the Medtech business unit, which was sold in April 2016, are not included.